Momenta Pharmaceuticals and Mylan N.V. announced today that M834, the companies’ proposed biosimilar of Bristol-Myers Squibb’s Orencia (abatacept), did not meet its primary pharmacokinetic (PK) endpoints in a phase 1 study comparing the PK, safety, and immunogenicity of M834 compared with US- and EU-sourced Orencia.
Momenta Pharmaceuticals and Mylan N.V.
today that M834, the companies’ proposed biosimilar of Bristol-Myers Squibb’s Orencia (abatacept), did not meet its primary pharmacokinetic (PK) endpoints in a phase 1 study comparing the PK, safety, and immunogenicity of M834 compared with US- and EU-sourced Orencia.
The phase 1
was a randomized, double-blind, 3-arm, parallel-group, single-dose, subcutaneous administration clinical study in 243 healthy volunteers ages 18 to 55.
Primary outcome measures included:
Secondary outcome measures included:
Orencia is approved in the United States, European Union, and Japan for the treatment of rheumatoid arthritis (RA), including the treatment of those patients who have not been helped enough by other medicines for RA. Orencia may be used in adults alone or with RA treatments other than tumor necrosis factor (TNF) antagonists. In the United States and European Union, Orencia is also approved for the treatment of psoriatic arthritis and juvenile idiopathic arthritis.
In 2016, worldwide
of Orencia totaled $2.4 billion. There are no currently approved abatacept biosimilars; the patents on the originator product expire in the US in October 2019 and in Europe in December 2017.
According to an August 2017 study published in Clinical Therapeutics, the overall cost per patient per year of infusion therapy for Orencia was $46,532.
The Generics and Biosimilars Initiative
that the only other abatacept biosimilar being developed is that of BioXpress Therapeutics.
Craig Wheeler, president and CEO of Momenta Pharmaceuticals, said that the phase 1 results were unexpected and disappointing. “We are in the process of gathering the full data set and will work with Mylan to fully analyze these data to better understand the study results and evaluate next steps for this program,” he said. “We remain committed to executing on our biosimilar portfolio.”
Mylan and Momenta are collaborating on biosimilars, and are jointly responsible for product development, with Mylan leading worldwide commercialization efforts.
Momenta’s biosimilar pipeline includes a number of programs, but only 2 have been publicly disclosed—M834 and a biosimilar of adalimumab (AbbVie’s Humira), M923.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
May 16th 2024Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.